Mycophenolate mofetil: A safe and promising immunosuppressant in neuromuscular diseases

V. Chaudhry, D. R. Cornblath, J. W. Griffin, R. O'Brien, D. B. Drachman

Research output: Contribution to journalArticle

Abstract

The authors report the use mycophenolate mofetil (MM) in the treatment of neuromuscular diseases. Thirty-eight patients (32 with MG, three with inflammatory myopathy, and three with chronic acquired demyelinating neuropathy) were treated with MM for an average duration of 12 months. All patients tolerated MM without major side effects. Twenty-four patients improved either in their functional status or in their ability to reduce corticosteroid dose. Mean time to improvement was 5 months.

Original languageEnglish (US)
Pages (from-to)94-96
Number of pages3
JournalNeurology
Volume56
Issue number1
DOIs
StatePublished - Jan 9 2001

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Mycophenolate mofetil: A safe and promising immunosuppressant in neuromuscular diseases'. Together they form a unique fingerprint.

  • Cite this